Intraarterial iododeoxyuridine infusion combined with irradiation. A pilot study.
The halogenated pyrimidine, iododeoxyuridine (IUdR), enhances cytotoxicity of ionizing irradiation experimentally. Continuous intraarterial infusion of IUdR was combined with irradiation to maximize drug concentration in tumor and reduce potential systemic toxicity. Percutaneous tumor-specific artery catheterization was utilized in five patients, with delivery of IUdR (20 mg/kg/day) by continuous infusion 5 days prior to irradiation treatments and continued for 10-14 days. Infusion vessels included the internal mammary, the internal iliac, the renal, the common femoral, and the bronchial arteries. Conventional radiotherapy fields, fractionation, and total doses were utilized, and therapy was well tolerated. Low-grade leukopenia and thrombocytopenia was observed several weeks following infusion. A clinically nonsignificant skin reaction was observed within the irradiation fields 2-3 weeks after initiation of irradiation in several patients. No alopecia or stomatitis was observed. This study minimizes initial hepatic dehalogenation of IUdR when given by intraarterial administration. Two patients have been free of disease for over 20 years, with no long-term toxicity from IUdR therapy.
Wirtanen
G W
GW
Department of Human Oncology, University of Wisconsin School of Medicine, Madison.
Wiley
A L
AL
Vermund
H
H
Stephenson
J A
JA
Ansfield
F J
FJ
D000293:Adolescent; D000328:Adult; D002406:Catheterization, Peripheral; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007065:Idoxuridine / Q000008:administration & dosage / Q000627:therapeutic use*; D007261:Infusions, Intra-Arterial; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000098:blood supply / Q000532:radiotherapy*; D010865:Pilot Projects; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D011879:Radiotherapy Dosage
D011838:Radiation-Sensitizing Agents; D007065:Idoxuridine